Jun 25, 2025 6:15pm EDT Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Apr 17, 2025 7:00am EDT Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada
Apr 07, 2025 7:00am EDT Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection
Mar 14, 2025 7:00am EDT Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
Feb 24, 2025 7:00am EST Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
Feb 05, 2025 5:30pm EST Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
Feb 04, 2025 7:00am EST Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
Jan 31, 2025 8:38am EST Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares
